232 related articles for article (PubMed ID: 36555268)
1. Association of BRAF
Attia AS; Hussein M; Issa PP; Elnahla A; Farhoud A; Magazine BM; Youssef MR; Aboueisha M; Shama M; Toraih E; Kandil E
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555268
[TBL] [Abstract][Full Text] [Related]
2. BRAF
Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
[TBL] [Abstract][Full Text] [Related]
3. BRAF
Zhao H; Liu CH; Lu Y; Liu SZ; Yeerkenbieke P; Cao Y; Xia Y; Gao LY; Liu YW; Liu ZW; Chen SG; Liang ZY; Li XY
Oral Oncol; 2024 May; 152():106755. PubMed ID: 38547780
[TBL] [Abstract][Full Text] [Related]
4. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
5. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma.
Kim KJ; Kim SG; Tan J; Shen X; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Xing M
Eur J Cancer; 2020 Jan; 124():161-169. PubMed ID: 31790974
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm.
Silver JA; Bogatchenko M; Pusztaszeri M; Forest VI; Hier MP; Yang JW; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2021 Nov; 50(1):63. PubMed ID: 34742355
[TBL] [Abstract][Full Text] [Related]
7. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.
Choi SY; Park H; Kang MK; Lee DK; Lee KD; Lee HS; Kim SW; Lee EN; Hong JC
World J Surg Oncol; 2013 Nov; 11():291. PubMed ID: 24228637
[TBL] [Abstract][Full Text] [Related]
8. BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis.
Ma YJ; Deng XL; Li HQ
J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):591-599. PubMed ID: 26223933
[TBL] [Abstract][Full Text] [Related]
9. BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis.
Chen Y; Sadow PM; Suh H; Lee KE; Choi JY; Suh YJ; Wang TS; Lubitz CC
Thyroid; 2016 Feb; 26(2):248-55. PubMed ID: 26671072
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
11. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.
Li F; Chen G; Sheng C; Gusdon AM; Huang Y; Lv Z; Xu H; Xing M; Qu S
Endocr Relat Cancer; 2015 Apr; 22(2):159-68. PubMed ID: 25593071
[TBL] [Abstract][Full Text] [Related]
12. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
[TBL] [Abstract][Full Text] [Related]
13. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases.
Zheng X; Wei S; Han Y; Li Y; Yu Y; Yun X; Ren X; Gao M
Ann Surg Oncol; 2013 Jul; 20(7):2266-73. PubMed ID: 23370668
[TBL] [Abstract][Full Text] [Related]
14. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
[TBL] [Abstract][Full Text] [Related]
15. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.
Lin KL; Wang OC; Zhang XH; Dai XX; Hu XQ; Qu JM
Ann Surg Oncol; 2010 Dec; 17(12):3294-300. PubMed ID: 20953721
[TBL] [Abstract][Full Text] [Related]
16. A Significance of Concomitant BRAF
Kuchareczko A; Kopczyński J; Kowalik A; Hińcza-Nowak K; Walczyk A; Pałyga I; Trybek T; Szymonek M; Gąsior-Perczak D; Gadawska-Juszczyk K; Mikina E; Płachta I; Suligowska A; Płusa A; Chrapek M; Łopatyński T; Góźdź S; Kowalska A
Thyroid; 2022 Nov; 32(11):1372-1381. PubMed ID: 35950639
[No Abstract] [Full Text] [Related]
17. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
Liu C; Chen T; Liu Z
World J Surg Oncol; 2016 Sep; 14(1):241. PubMed ID: 27600854
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Tufano RP; Teixeira GV; Bishop J; Carson KA; Xing M
Medicine (Baltimore); 2012 Sep; 91(5):274-286. PubMed ID: 22932786
[TBL] [Abstract][Full Text] [Related]
19. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
Zhang Q; Liu SZ; Zhang Q; Guan YX; Chen QJ; Zhu QY
Cell Physiol Biochem; 2016; 38(2):763-76. PubMed ID: 26871894
[TBL] [Abstract][Full Text] [Related]
20. [Correlation between Ultrasound-guided Fine-needle Aspiration Combined with BRAF
Zhang Y; Luo YK; Zhang Y; Zhang MB; Guang Y; Xie F; Jiang B; Tang J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Aug; 41(4):517-523. PubMed ID: 31484615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
